Drug · Small Molecule

Bafetinib

CI-DRUG-00000099Explore in graph →NCIt C62516 CHEMBL206834 CIViC Phase 2

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Trials	Jurisdictions	First approval	First trial
All cancers	Phase2	Phase 2	4	—	—	2006-07
Leukemia	Phase2	Phase 2	2	—	—	2006-07
Malignant Central Nervous System Neoplasm	Phase1	Phase 1	1	—	—	2010-12

Computedclinicaltrials

Curated evidence

Clinical evidence (14)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–14 of 14 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ABCB1 Overexpression1
Bafetinib + Dasatinib

Clinical trials

Trials with this intervention (4)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–4 of 4 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01234740	Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases	completed	Phase 1	7	City of Hope Medical CenterOTHER	1	Apr 17, 2018	clinicaltrials
NCT01144260	Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)	completed	Phase 2

ABL1 Fusion1
Bafetinib + Dasatinib + NilotinibSubstitutes	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID7838 In an in vitro study, six CML cell lines expressing the BCR-ABL1 fusion protein showed sensitivity to nilotinib (IC50: 24.3-84.5 nM), dasatinib (IC50: 1.5-10.9 nM), and bafetinib (IC50: 11.8-87.7 nM).… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic

ABL1 Fusion1

Bafetinib + Dasatinib + NilotinibSubstitutes

Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS

Predictive

Supports Sensitivity Response

accepted

EID7838

In an in vitro study, six CML cell lines expressing the BCR-ABL1 fusion protein showed sensitivity to nilotinib (IC50: 24.3-84.5 nM), dasatinib (IC50: 1.5-10.9 nM), and bafetinib (IC50: 11.8-87.7 nM).… (full text at CIViC)

PMID 18191450 · Deguchi et al., 2008 · Open in CIViC

civic

LYN OVEREXPRESSION1
Bafetinib + DasatinibSubstitutes	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Does Not Support Resistance	3	accepted	EID7874 The BCR-ABL1 expressing imatinib-resistant cell line MYL-R overexpresses LYN, an SRC family kinase. Dasatinib showed the most potency against MYL-R compared to the non-resistant MYL cell line (IC50: 6… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic

LYN OVEREXPRESSION1

Bafetinib + DasatinibSubstitutes

Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS

Predictive

Does Not Support Resistance

accepted

EID7874

The BCR-ABL1 expressing imatinib-resistant cell line MYL-R overexpresses LYN, an SRC family kinase. Dasatinib showed the most potency against MYL-R compared to the non-resistant MYL cell line (IC50: 6… (full text at CIViC)

PMID 18191450 · Deguchi et al., 2008 · Open in CIViC

civic

ABL1 F317L + ABL1 Fusion1
Bafetinib + NilotinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Resistance	3	accepted	EID2677 In an in vitro study, a Ba/F3 cell line stably expressing the F317L mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to nilotinib and bafetinib treat… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic

ABL1 F317L + ABL1 Fusion1

Bafetinib + NilotinibSubstitutes

Malignant NeoplasmALIAS

Predictive

Does Not Support Resistance

accepted

EID2677

In an in vitro study, a Ba/F3 cell line stably expressing the F317L mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to nilotinib and bafetinib treat… (full text at CIViC)

PMID 18191450 · Deguchi et al., 2008 · Open in CIViC

civic

ABL1 F317V + ABL1 Fusion1
Bafetinib + Imatinib + NilotinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Resistance	3	accepted	EID7843 In an in vitro study, a Ba/F3 cell line stably expressing the dasatinib-resistance variant F317V in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to imatinib,… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic

ABL1 F317V + ABL1 Fusion1

Bafetinib + Imatinib + NilotinibSubstitutes

Malignant NeoplasmALIAS

Predictive

Does Not Support Resistance

accepted

EID7843

In an in vitro study, a Ba/F3 cell line stably expressing the dasatinib-resistance variant F317V in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to imatinib,… (full text at CIViC)

PMID 18191450 · Deguchi et al., 2008 · Open in CIViC

civic

ABL1 G250E + ABL1 Fusion1
Bafetinib + ImatinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	accepted	EID7853 In an in vitro study, a Ba/F3 cell line stably expressing the G250E mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to imatinib and bafetinib (INNO-406) trea… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic

ABL1 G250E + ABL1 Fusion1

Bafetinib + ImatinibSubstitutes

Malignant NeoplasmALIAS

Predictive

Supports Resistance

accepted

EID7853

In an in vitro study, a Ba/F3 cell line stably expressing the G250E mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to imatinib and bafetinib (INNO-406) trea… (full text at CIViC)

PMID 18191450 · Deguchi et al., 2008 · Open in CIViC

civic

ABL1 H396P + ABL1 Fusion1
Bafetinib + NilotinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Resistance	3	accepted	EID7846 In an in vitro study, a Ba/F3 cell line stably expressing H396P in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to nilotinib and bafetinib (INNO-406) treatme… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic

ABL1 H396P + ABL1 Fusion1

Bafetinib + NilotinibSubstitutes

Malignant NeoplasmALIAS

Predictive

Does Not Support Resistance

accepted

EID7846

In an in vitro study, a Ba/F3 cell line stably expressing H396P in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to nilotinib and bafetinib (INNO-406) treatme… (full text at CIViC)

PMID 18191450 · Deguchi et al., 2008 · Open in CIViC

civic

ABL1 M244V + ABL1 Fusion1
Bafetinib + ImatinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	accepted	EID7850 In an in vitro study, a Ba/F3 cell line stably expressing the M244V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to imatinib and bafetinib (INNO-406) trea… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic

ABL1 M244V + ABL1 Fusion1

Bafetinib + ImatinibSubstitutes

Malignant NeoplasmALIAS

Predictive

Supports Resistance

accepted

EID7850

In an in vitro study, a Ba/F3 cell line stably expressing the M244V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to imatinib and bafetinib (INNO-406) trea… (full text at CIViC)

PMID 18191450 · Deguchi et al., 2008 · Open in CIViC

civic

ABL1 M351T + ABL1 Fusion1
Bafetinib + Dasatinib + NilotinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Resistance	3	accepted	EID2686 In an in vitro study, a Ba/F3 cell line stably expressing the M351T mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to nilotinib, dasatinib, and baf… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic

ABL1 M351T + ABL1 Fusion1

Bafetinib + Dasatinib + NilotinibSubstitutes

Malignant NeoplasmALIAS

Predictive

Does Not Support Resistance

accepted

EID2686

In an in vitro study, a Ba/F3 cell line stably expressing the M351T mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to nilotinib, dasatinib, and baf… (full text at CIViC)

PMID 18191450 · Deguchi et al., 2008 · Open in CIViC

civic

ABL1 Q252H + ABL1 Fusion1
Bafetinib + ImatinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	accepted	EID7849 In an in vitro study, a Ba/F3 cell line stably expressing the Q252H mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to imatinib and bafetinib (INNO-406) trea… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic

ABL1 Q252H + ABL1 Fusion1

Bafetinib + ImatinibSubstitutes

Malignant NeoplasmALIAS

Predictive

Supports Resistance

accepted

EID7849

In an in vitro study, a Ba/F3 cell line stably expressing the Q252H mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to imatinib and bafetinib (INNO-406) trea… (full text at CIViC)

PMID 18191450 · Deguchi et al., 2008 · Open in CIViC

civic

ABL1 T315A + ABL1 Fusion1
Bafetinib + NilotinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Resistance	3	accepted	EID7842 In an in vitro study, a Ba/F3 cell line stably expressing the dasatinib-resistance variant T315A in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to nilotinib… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic

ABL1 T315A + ABL1 Fusion1

Bafetinib + NilotinibSubstitutes

Malignant NeoplasmALIAS

Predictive

Does Not Support Resistance

accepted

EID7842

In an in vitro study, a Ba/F3 cell line stably expressing the dasatinib-resistance variant T315A in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to nilotinib… (full text at CIViC)

PMID 18191450 · Deguchi et al., 2008 · Open in CIViC

civic

ABL1 T315I + ABL1 Fusion1
Bafetinib + Dasatinib + Imatinib + NilotinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	accepted	EID2671 In an in vitro study, a Ba/F3 cell line stably expressing the T315I mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib, imatinib, dasatinib, and ba… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic

ABL1 T315I + ABL1 Fusion1

Bafetinib + Dasatinib + Imatinib + NilotinibSubstitutes

Malignant NeoplasmALIAS

Predictive

Supports Resistance

accepted

EID2671

In an in vitro study, a Ba/F3 cell line stably expressing the T315I mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib, imatinib, dasatinib, and ba… (full text at CIViC)

PMID 18191450 · Deguchi et al., 2008 · Open in CIViC

civic

ABL1 Y253F + ABL1 Fusion1
Bafetinib + Dasatinib + NilotinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Resistance	3	accepted	EID2658 In an in vitro study, a Ba/F3 cell line stably expressing the Y253F mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to nilotinib, dasatinib, and baf… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic

ABL1 Y253F + ABL1 Fusion1

Bafetinib + Dasatinib + NilotinibSubstitutes

Malignant NeoplasmALIAS

Predictive

Does Not Support Resistance

accepted

EID2658

In an in vitro study, a Ba/F3 cell line stably expressing the Y253F mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to nilotinib, dasatinib, and baf… (full text at CIViC)

PMID 18191450 · Deguchi et al., 2008 · Open in CIViC

civic

PDGFRB Fusion1
Bafetinib + Dasatinib + Imatinib + Nilotinib + Ponatinib + RebastinibSubstitutes	Childhood B-cell Acute Lymphoblastic LeukemiaUNRESOLVED	Predictive	D	Supports Sensitivity Response	4	submitted	EID7196 In vitro studies in Ba/F3 murine cells. Cells transduced with tetracycline-inducible ATF7IP-PDGFRB were capable of proliferating in an IL-3-independent manner and had a gene expression pattern overlap… (full text at CIViC) PMID 26703895 · Ishibashi et al., 2016 · Open in CIViC	civic

PDGFRB Fusion1

Bafetinib + Dasatinib + Imatinib + Nilotinib + Ponatinib + RebastinibSubstitutes

Childhood B-cell Acute Lymphoblastic LeukemiaUNRESOLVED

Predictive

Supports Sensitivity Response

submitted

EID7196

In vitro studies in Ba/F3 murine cells. Cells transduced with tetracycline-inducible ATF7IP-PDGFRB were capable of proliferating in an IL-3-independent manner and had a gene expression pattern overlap… (full text at CIViC)

PMID 26703895 · Ishibashi et al., 2016 · Open in CIViC

civic